• Je něco špatně v tomto záznamu ?

Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats

RR. Horsley, T. Páleníček, J. Kolin, K. Valeš,

. 2018 ; 29 (6) : 530-536. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035354

Short-term moderate doses of serotonergic and dissociative hallucinogens can be useful in the treatment of anxiety. Recently, a trend has developed for long-term intermittent 'microdosing' (usually one-tenth of a 'full' active dose), with reports of long-lasting relief from anxiety and related disorders; however, there is no scientific evidence for the efficacy of therapeutic microdosing nor to show its lasting effects. The objective of this study was to test for lasting effects on anxiety in rats after microdosing with ketamine or psilocin. Over 6 days, Wistar rats (N=40) were administered ketamine (0.5 or 3 mg/kg), psilocin (0.05 or 0.075 mg/kg), or saline on three occasions. A 5-min elevated plus-maze test was conducted 48 h after the final drug treatment (n=8). Dependent variables were entries (frequency), spent time (%), and distance traveled (cm) in each zone, as well as total frequency of rears, stretch-attend postures, and head dips. Statistical analyses of drug effects used separate independent one-way analysis of variance and pair-wise comparisons using independent t-tests. Statistical effects were modest or borderline and were most consistent with a mildly anxiogenic profile, which was significant at lower doses; however, this conclusion remains tentative. The lower doses of ketamine and psilocin produced comparable effects (to one another) across each variable, as did the higher doses. This pattern of effects may suggest a common (e.g. neurotransmitter/receptor) mechanism. We conclude that microdosing with hallucinogens for therapeutic purposes might be counter-productive; however, more research is needed to confirm our findings and to establish their translational relevance to clinical 'psychedelic' therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035354
003      
CZ-PrNML
005      
20191011082641.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/FBP.0000000000000394 $2 doi
035    __
$a (PubMed)29537989
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Horsley, Rachel R $u National Institute of Mental Health CZ, Klecany.
245    10
$a Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats / $c RR. Horsley, T. Páleníček, J. Kolin, K. Valeš,
520    9_
$a Short-term moderate doses of serotonergic and dissociative hallucinogens can be useful in the treatment of anxiety. Recently, a trend has developed for long-term intermittent 'microdosing' (usually one-tenth of a 'full' active dose), with reports of long-lasting relief from anxiety and related disorders; however, there is no scientific evidence for the efficacy of therapeutic microdosing nor to show its lasting effects. The objective of this study was to test for lasting effects on anxiety in rats after microdosing with ketamine or psilocin. Over 6 days, Wistar rats (N=40) were administered ketamine (0.5 or 3 mg/kg), psilocin (0.05 or 0.075 mg/kg), or saline on three occasions. A 5-min elevated plus-maze test was conducted 48 h after the final drug treatment (n=8). Dependent variables were entries (frequency), spent time (%), and distance traveled (cm) in each zone, as well as total frequency of rears, stretch-attend postures, and head dips. Statistical analyses of drug effects used separate independent one-way analysis of variance and pair-wise comparisons using independent t-tests. Statistical effects were modest or borderline and were most consistent with a mildly anxiogenic profile, which was significant at lower doses; however, this conclusion remains tentative. The lower doses of ketamine and psilocin produced comparable effects (to one another) across each variable, as did the higher doses. This pattern of effects may suggest a common (e.g. neurotransmitter/receptor) mechanism. We conclude that microdosing with hallucinogens for therapeutic purposes might be counter-productive; however, more research is needed to confirm our findings and to establish their translational relevance to clinical 'psychedelic' therapy.
650    _2
$a zvířata $7 D000818
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a antagonisté excitačních aminokyselin $x farmakologie $7 D018691
650    _2
$a halucinogeny $x farmakologie $7 D006213
650    _2
$a ketamin $x farmakologie $7 D007649
650    _2
$a lokomoce $x účinky léků $7 D008124
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a bludiště - učení $x účinky léků $7 D018782
650    _2
$a psilocybin $x analogy a deriváty $x farmakologie $7 D011562
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Páleníček, Tomáš $u National Institute of Mental Health CZ, Klecany. 3rd Medical Faculty, Charles University in Prague.
700    1_
$a Kolin, Jan $u National Institute of Mental Health CZ, Klecany. Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Valeš, Karel $u National Institute of Mental Health CZ, Klecany. Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
773    0_
$w MED00000661 $t Behavioural pharmacology $x 1473-5849 $g Roč. 29, č. 6 (2018), s. 530-536
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29537989 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011083101 $b ABA008
999    __
$a ok $b bmc $g 1452014 $s 1073904
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 29 $c 6 $d 530-536 $e - $i 1473-5849 $m Behavioural pharmacology $n Behav Pharmacol $x MED00000661
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...